Pressure BioSciences (PBIO) to Consider Strategic Financing and Spin-off Options

Posted by Laura Swartz

June 26, 2014 at 4:33 PM

Today Pressure BioSciences, Inc. (PBIO-OTC) announced a relationship with IssuWorks, a company that strives to provide services and technology to improve capital formation, distribution, and aftermarket results for issuers, investors, and investment banks. Pressure BioSciences has retained IssuWorks and its management team to review the Company’s strategic and financing alternatives, including the possible spin-off of vertical market applications into new, stand-alone businesses.

Read More

Topics: Pressure BioSciences

NEW RESEARCH: 12-page Quarterly Update Available on Pressure BioSciences (PBIO)

Posted by Laura Swartz

June 16, 2014 at 4:58 PM

This afternoon, we published an update on Pressure BioSciences, Inc. (PBIO-OTC), a company focused on the development and commercialization of proprietary laboratory instruments and consumable products. The update covers the company's most recently reported financial results for the first quarter 2014 and highlights from fiscal year 2013, as well as describes new product introductions, including a new pressure cycling technology (PCT) platform being introduced this week at the annual meeting of the American Society for Mass Spectrometry.

Read More

Topics: Pressure BioSciences

NEW RESEARCH: Saleen Automotive Poised for Growth

Posted by Laura Swartz

June 12, 2014 at 11:30 AM

This morning, we released a new 60-page Executive Informational Overview (EIO) on legendary car manufacturer, Saleen Automotive, Inc. (SLNN-OTC). Saleen designs and manufactures mass customized American sports cars, supercars, and race cars. The Company has also recently entered the electric vehicle (EV) market.

Saleen’s primary product line entails high-performance cars built from the base chassis of Ford Mustangs, Chevrolet Camaros, and Dodge Challengers, with an expected summer 2014 launch of a Saleen EV built on the chassis of Consumer Reports’ 2014 car of the year, the Tesla Model S. The Company also plans to launch a new supercar within the next two years to compete against exotic imports. Saleen’s first supercar, the Saleen S7, was built entirely by the Company from initial design concepts to finished production and sale within nine months, and a race-tuned edition went on to win 78 races, including 10 championships and the 2010 24 Hours of Le Mans. 

Saleen 302 SA-30 Mustang in Pearl White
Read More

Topics: Saleen

NEW RESEARCH: 12-page Quarterly Update on Boston Therapeutics ($BTHE)

Posted by Laura Swartz

June 11, 2014 at 3:22 PM

A 12-page Quarterly Update on Boston Therapeutics, Inc. (BTHE-OTC) is now available here. The update covers the company's news and developments since the publication of a 60-page Executive Informational Overview in March.

Read More
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic